Trial (first author, publication year) Interventions (only comparisons relevant to this meta-analysis listed) Randomised participants (
) Timing of outcome assessment PASI 75 [
(%)] PGA 0/1 [
(%)] Etanercept trials
Papp et al., 2005 [9 ] Intervention: Etanercept 50 mg BIW for 12 weeks, then 25 mg BIW for 12 weeks. 203 Week 24 102 (50%) NA Control intervention: Placebo BIW for 12 weeks, then 25 mg BIW for 12 weeks. 204 Week 12 6 (3%) NA Bagel et al., 2012 [19 ] Intervention: Etanercept 50 mg BIW for 12 weeks, then 50 mg QW for 12 weeks. 62 Week 24 43 (69%) 39 (63%) Control intervention: Placebo BIW for 12 weeks, then 50 mg BIW for 12 weeks. 62 Week 12 3 (5%) 3 (5%) Adalimumab trials Gordon et al., 2006 [10 ] Intervention: Adalimumab 80 mg at week 0, then 40 mg EOW starting at week 1. 46 Week 24 29 (63%) 29 (63%) Control intervention: Placebo QW, then adalimumab 80 mg at week 12, followed by 40 mg EOW from week 13 on. 52 Week 12 2 (4%) NA Menter et al., 2008 [12 ] Intervention: Adalimumab 80 mg at week 0, then 40 mg EOW starting at week 1. 814 Week 24 570 (70%) 488 (60%) Control intervention: Placebo QW at week 0, then EOW beginning
week 1 and through week 15, followed by 40 mg EOW from week 16 on. 398 Week 16 26 (7%) 16 (4%) Asahina et al., 2010 [14 ] Intervention: Adalimumab 80 mg at week 0, then 40 mg EOW starting at week 2. 43 Week 24 30 (70%) 25 (58%) Control intervention: Placebo EOW for 24 weeks. 46 Week 24 6 (13%) 5 (11%) Infliximab trials Reich et al., 2005 [15 ] Intervention: Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks. 301 Week 24 227 (75.4%) 203 (67.4%) Control intervention: Placebo at weeks 0, 2, and 6, then every 8 weeks. 77 Week 24 3 (3.8%) 2 (2.6%) Menter et al., 2007 [16 ] Intervention: Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 week. 150 Week 26 110 (73.3%) 112 (74.6%) Control intervention Placebo at weeks 0, 2, and 6, switched to infliximab 5 mg/kg at week 16. 208 Week 10 4 (1.9%) 2 (1%)
Torii and Nakagawa 2010 [17 ] Intervention: Infliximab 5 mg/kg at weeks 0, 2, and 6, then every 8 weeks. 35 Week 26 24 (68.6%) 28 (80%) Control intervention: Placebo at weeks 0, 2, and 6, switched to infliximab 5 mg/kg at weeks 16. 19 Week 10 0 (0%) 2 (10.5%) Ustekinumab trials Leonardi et al., 2008 [11 ] Intervention: (i) Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks. 255 Week 28 178 (71%) 147 (58%) (ii) Ustekinumab 90 mg at weeks 0 and 4, then every 12 weeks. 256 Week 28 191 (75%) 161 (63%) Control intervention: Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks. 255 Week 12 8 (3%) 10 (4%) Papp et al., 2008 [13 ] Intervention: (i) Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks. 409 Week 28 276 (67%) 243 (59%) (ii) Ustekinumab 90 mg at weeks 0 and 4, then every 12 weeks. 411 Week 28 314 (76%) 280 (68%) Control intervention: Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks. 410 Week 12 15 (4%) 20 (5%) Tsai et al., 2011 [18 ] Intervention: Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks. 61 Week 28 42 (69%) 40 (66%) Control intervention: Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks. 60 Week 12 3 (5%) 5 (8%) Igarashi et al., 2012 [20 ] Intervention: (i) Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks. 65 Week 28 44 (68%) NA (ii) Ustekinumab 90 mg at weeks 0 and 4, then every 12 weeks. 62 Week 28 42 (68%) NA Control intervention: Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks. 33 Week 12 2 (6%) 3 (9%) Zheng et al., 2012 [21 ] Intervention: Ustekinumab 45 mg at weeks 0 and 4, then every 12 weeks. 160 Week 28 140 (88%) 132 (83%) Control intervention: Placebo at weeks 0 and 4, then ustekinumab 45 or 90 mg every 12 weeks. 162 Week 12 18 (11%) 24 (15%)